Zenrelia: A new treatment to elevate care in canine allergic and atopic dermatitis
This session will focus on your treatment targets when treating atopic patients, data from the Zenrelia clinical trials and real-world experience with Zenrelia from some of the UK’s leading dermatologists.
Learn about Zenrelia (ilunocitinib), Elanco’s new once-daily JAK inhibitor for the treatment of canine allergic and atopic dermatitis which brings 45% more itchy dogs back to normal compared with Apoquel* [1]. Launched in the UK this Summer, Zenrelia has already been used to treat over 800,000 dogs in Brazil, the USA, Japan and Canada since its first launch last year [2].
*77% of dogs treated with Zenrelia achieved PVAS <2 by Day 112 compared to 53% of dogs treated with Apoquel. A ‘normal’ itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS <2).[1] 1. Forster S et al. Vet Dermatol. 2025 Apr;36(2):165–76. 2. Elanco Animal Health. Elanco Global Sales Data. Sept 2025.
- Learn about what to aim for when treating atopic dermatitis
- Learn about how Zenrelia brings more itchy dogs back to normal
- Learn about how best to use Zenrelia in your every day practice to achieve better outcomes for your patients
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
)
)
)
)
)
){kind=logo}
)
)
){kind=logo}
)
)
)
)
)
)
)
)
){kind=logo}
){kind=logo}